Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521739 | 0.90 | RAB9A (0.49) | PPARGKMT2AACACB | |
| SCHEMBL2525703 | 0.88 | ITGB3 (0.62) | ITGB3ITGA2BPPARG | |
| SCHEMBL2186966 | 0.88 | ITGB3 (0.62) | ITGB3ITGA2BPPARG | |
| SCHEMBL12214839 | 0.88 | ITGB3 (0.62) | ITGB3ITGA2BPPARG | |
| SCHEMBL2219572 | 0.88 | ITGB3 (0.66) | ITGB3ITGA2BPPARGITGA4ITGB7 | |
| SCHEMBL2219578 | 0.88 | ITGB3 (0.66) | ITGB3ITGA2BPPARGITGA4ITGB7 | |
| SCHEMBL7086188 | 0.88 | ITGB3 (0.66) | ITGB3ITGA2BPPARGITGA4ITGB7 | |
| SCHEMBL6893824 | 0.84 | ALDH1A1 (0.52) | PPARGKMT2A | |
| SCHEMBL6893819 | 0.84 | ALDH1A1 (0.52) | PPARGKMT2A | |
| SCHEMBL10663117 | 0.82 | LDHA (0.63) | ITGB3ITGA2BPPARGITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| EP-1836159-B1 | Antibiotic binaphthyl derivatives | UNIV WOLLONGONG (AU) | 2013-04-10 | — | — | EP | disclosed |
| EP-1836159-B1 | Antibiotic binaphthyl derivatives | UNIV WOLLONGONG (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| US-8039430-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-10-18 | — | — | US | disclosed |
| US-8039430-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-10-18 | — | — | US | disclosed |
| US-8039430-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-10-18 | — | — | US | disclosed |
| EP-2199300-A2 | Peptidic compounds | The University Of Wollongong (AU) | 2010-06-23 | — | — | EP | disclosed |
| EP-2199300-A2 | Peptidic compounds | The University Of Wollongong (AU) | 2010-06-23 | — | — | EP | disclosed |
| EP-1836159-A4 | PEPTIDIC COMPOUNDS | UNIV WOLLONGONG (AU) | 2009-02-25 | — | — | EP | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| EP-1836159-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006074501-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006074501-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300287-A1 | Peptidic Compounds | VIP, NGLY1, FURIN | ITGB3 2966/4885ITGA2B 4105/4885PPARG 3977/4885 |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | VIP, NGLY1, FURIN | ITGB3 2456/4885ITGA2B 3961/4885PPARG 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.